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Abstract
Background: Lactoferrin (LF) is an 80 kDa glycoprotein which is known for its effects against bacteria, viruses and
other pathogens. It also has a high potential in nutrition therapy and welfare of people and a variety of animals,
including piglets. The ability to bind lipopolysaccharide (LPS) is one of the described anti-inflammatory mechanisms
of LF. Previous studies suggested that cells can be stimulated even by LPS-free LF. Therefore, the aim of our study
was to bring additional information about this possibility. Porcine monocyte derived macrophages (MDMF) and
human embryonic kidney (HEK) cells were stimulated with unpurified LF in complex with LPS and with purified LF
without bound LPS.
Results: Both cell types were stimulated with unpurified as well as purified LF. On the other hand, neither HEK0
cells not expressing any TLR nor HEK4a cells transfected with TLR4 produced any pro-inflammatory cytokine
transcripts after stimulation with purified LF. This suggests that purified LF without LPS stimulates cells via another
receptor than TLR4. An alternative, TLR4-independent, pathway was further confirmed by analyses of the NF-kappa-
B-inducing kinase (NIK) activation. Western blot analyses showed NIK which activates different NFκB subunits
compared to LF-LPS signaling via TLR4. Though, this confirmed an alternative pathway which is used by the
purified LF free of LPS. This stimulation of MDMF led to low, but significant amounts of pro-inflammatory cytokines,
which can be considered as a positive stimulation of the immune system.
Conclusion: Our results suggest that LF’s ability is not only to bind LPS, but LF itself may be a stimulant of
pro-inflammatory pathways.
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Background
Lactoferrin (LF) is an 80 kDa iron-binding glycoprotein
that plays an important role in the innate immune system
[1–7]. It is also a multifunctional protein with a supportive
therapeutic potential against bacterial, fungal or viral in-
fections [8–10]. At present, LF is the focus of a variety of
research areas due to its anti-inflammatory and anti-
cancer properties, and the resulting therapeutical potential
[11–14]. It was found that LF interacts with LPS and then
activates NFκB via TLR4 pathway [15]. This suggests that
immunomodulatory effects of LF could be due, in part, to
LPS binding [16, 17]. To date, it is known that bovine LF
affects the innate immunity by activating specific events in
macrophages through interaction with TLR4-dependent
and TLR4-independent pathways. It was found that bo-
vine LF function is not dependent on TLR4 with respect
to IL-6 production [18]. Since LF has a broad spectrum of
actions, it also uses a wide range of signaling pathways for
this purpose. In addition to NFκB, LF affects also the
MAP kinase pathway. There, activation of ERK1/2 as
well as of p38 stress-activated kinase has been
reported [19, 20].
NF-kappa-B-inducing kinase also known as Mitogen-
activated protein kinase 14 (NIK) is encoded by the
MAP3K14 gene which is a serine/threonine protein kin-
ase [21]. NIK belongs to the group of relevant activators
of the NFκB alternative pathway [22]. Although it is
known that NIK is necessary for activation of the non-
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canonical pathway, it was first identified as a kinase
which activates the canonical pathway downstream of
TNF and IL-1 receptors. Physiological relevance of
NIK in the canonical NFκB activation was examined
by Zarnegar and coworkers. It was demonstrated that
the role of NIK is in the amplification of signals from
the canonical pathway. In concert with findings from
NIK over-expression studies, NIK activates the canon-
ical pathway when present at high levels due to
stabilization [23].
LF was tested for several applications, incl. as newborn
babies supplementation [24] or as a feed supplement for
newborn piglets [25, 26]. Although there are several pro-
ducing systems in which LF can be produced as recom-
binant [27, 28], bovine colostrum still remains as an
important source of bioactive constituents incl. LF [29].
Therefore, the aim of our study was to bring additional
information about the pathway used by bovine LF free of
LPS to stimulate porcine macrophages to the production
of proinflammatory cytokines.
Methods
Preparation of MDMF from CD14+ cells
CD14+ porcine monocytes were isolated from whole
blood of six 5–6 week–old pigs as described previously
[30]. Peripheral blood mononuclear cells (PBMC) were
isolated from the collected whole blood by density gradi-
ent centrifugation using Histopaque−1077 (Sigma).
CD14+ monocytes were purified from PBMC by staining
with mouse–anti–swine CD14 (clone MIL2, AbD Sero-
tec, Oxford, UK, 10 μl per 108 cells) and goat-anti-
mouse IgG MicroBeads followed by an immunomagnetic
separation method (QuadroMACS™ cell separator, Milte-
nyi Biotec, Gladbach, Germany). The cell subset purity
was assessed using flow cytometer LSRFortessaTM (BD
Biosciences, San Jose, CA) and was more than 95 % in
all cases. Purified CD14+ monocytes were cultured in
DMEM medium supplemented with 10 % fetal bovine
serum and 1 % antibiotics (Antibiotic Antimycotic Solu-
tion 100×: 10,000 units penicillin, 10 mg streptomycin,
and 25 μg amphotericin B per mL; Sigma-Aldrich) for
4 days to differentiate into macrophages (MDMF).
HEK cells preparation
HEK 293/hTLR4A-MD2-CD14 (HEK4a) cells expressing
human TLR4A, MD2 and CD14 molecules and control
HEK 293/null (HEK0) cells were obtained from Invivo-
gen (San Diego, USA). Cells were grown in DMEM
(Sigma) according to the manufacturer’s recommenda-
tion. The cells were seeded onto 24-well plates at the
density of 2 × 105 cells per well. A treatment was applied
as soon as the cells reached 80 % confluency.
Purification of lactoferrin
In the study, bovine colostral lactoferrin (Sigma-Aldrich,
USA). For part of the study, lactoferrin was purified
from LPS. This method was previously described [16].
The interaction between LPS and LF was abrogated by
NaCl concentrations higher than 0.4 M [15]. Ten mg of
LF (Sigma) was dissolved in 0.5 M NaCl of endotoxin-
free water (Sigma), and centrifuged with a 100-kDa
Centricon® Plus 70 (Millipore, Centricon, Merck KGaA)
to remove endotoxin from the LF. The filtrate, an endo-
toxin free LF in 0.5 NaCl solution, was desalted by
centrifugation with the 10-kDa Centricon® Plus 70. The
retentate was recovered, and the concentration was
quantified by Pierce BCA Protein Assay Kit 23225
(Thermo Scientific). The success of the purification was
estimated by Limulus Amebocyte Lysate QCL-1000™
(Lonza). Unpurified and purified LF contained 4.10 EU/ml
and 0.05 EU/ml, respectively.
Iron saturation determination
The level of iron saturation was estimated according to
already described method [31]. Briefly, lactoferrin before
and after LPS removal was spectroscopicaly measured at
280 and 466 nm with endotoxin-free water (Sigma-
Aldrich, USA) as a blank. UV/VIS spectra were ob-
tained using a microplate reader Synergy H1 (Biotek,
USA). The acquired A280/A466 ratios were subse-
quently used to determine the iron saturation apply-
ing the correlation curve established by Majka and
coworkers [31]. From accurate measurements by
ELISA and ICP-mass spectrometry. The estimation of
iron saturation was calculated from an equation:
A280=A466 ¼ a iron saturationð Þb; where a
¼ 933:0 47; b ¼ ‐0:817 0:056
Iron saturation was calculated as 64 and 32 % for un-
purified and purified LF, respectively.
Stimulation of HEK and MDMF
In the first experiments, HEK0 and HEK4a cells were
treated with 100 μg/ml and 250 μg/ml of lactoferrin to
prove the dose-dependent manner. In further experi-
ments, only the dose of 100 μg/ml was used. This dose
is sufficient for demonstrable stimulation of cells and is
also appropriate because there are significant losses of
starting material during purification of lactoferrin. Both
types of cells were stimulated with 100 μg/ml unpurified
or purified lactoferrin for 6 hours. After stimulation, the
cells were harvested. Then, the experiment was stopped
by aspiration of the medium and covering cells with RLT
buffer with mercaptoethanol (for RT-PCR analysis) or
Laemmli buffer (for Western blot analysis). All samples
were frozen and stored at −80 °C.
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Quantitative RT-PCR
Total RNA from each well was extracted using RNeasy
Mini Kit (Qiagen) according to the manufacturer’s in-
structions. mRNA was specifically reverse-transcribed
using the M-MLV reverse transcriptase system (Invitro-
gen, Paisley, UK) in the presence of oligo-dT primers.
cDNA was diluted 5× and 0.5 μl was used in qPCR. In
qPCR analysis, RNA expression was quantified in tripli-
cate reactions in a final volume of 3 μl in 384-well plates
using QuantiTect SYBR Green PCR master mix (Qiagen,
Hilden, Germany) following the manufacturer’s recom-
mendations, on a LightCycler 480 (Roche Applied
Science, http://www.roche.com/). qPCR reactions were
prepared with the assistance of Nanodrop II liquid
dispenser (Innovadyne Technologies, Rohnert Park, CA).
qPCR was performed under the following conditions:
denaturation (95 °C for 15 min) and 45 amplification
cycles (95 °C for 15 s, 58 °C for 30 s and 72 °C for 30 s).
The resulting melting curves were analyzed to test the
product specificity. Ten pmol of each primer pair was
used per reaction. Primers specific to 4 porcine and 2
human target genes and 2 porcine (HPRT, TBP-1) and 2
human (HPRT, GAPDH) reference genes were used for
simultaneous measurements of gene activity (Tables 1
and 2). Among the candidate reference genes, HPRT and
GAPDH in the case of MDMF and HEK, respectively,
were evaluated as the most constitutively expressed
genes in our samples and were selected to adjust mRNA
measurements. From the obtained data, relative expres-
sion of each target gene was calculated according to the
formula [1/(2target gene Ct)]/[1/(2reference gene Ct)].
Western blot analysis
For Western blot analysis, MDMF protein lysates were
prepared by adding lysis buffer (Cell Signaling Technology)
with Laemmli buffer (0.5 M Tris–HCl pH 6.8, glycerol,
10 % SDS, bromophenol blue, beta-mercaptoethanol,
deionized water), sonicated and heated to 95 °C for 5 min.
Protein lysates were resolved by 10 % SDS-PAGE. After gel
electrophoresis, proteins were transferred onto PVDF
(polyvinylidene difluoride) membranes. The membranes
were blocked in 5 % low-fat dry milk for 1 h at room
temperature and followed by incubation with primary
antibodies at 4 °C overnight. Primary antibodies used
for membrane probing-p-IκB (Ser 32) (Santa Cruz
Biotechnology), NIK antibody (Cell Signaling Technol-
ogy), anti-beta actin antibody (Abcam). Anti-beta
actin served as loading control. Next day, the mem-
branes were washed and probed with secondary anti-
bodies for 1 h at room temperature, followed by a
washing step. The proteins were visualized on a
photographic film, using ECL Plus Western blotting
detection reagents (GE Healthcare Life Sciences, UK).
Statistical analysis
Data were analysed using Statistica 12 (StatSoft). The
non-parametric test for paired samples (Wilcoxon’s
signed-rank test) was used to detect significant differ-
ences among groups. A p-value of <0.05 was considered
significant.
Results
mRNA production of CXCL-10, NFκB inhibitor, IL-8 and
TNFα by MDMF after LF treatment
Results in Fig. 1a-d suggest that both purified and
unpurified LF stimulated MDMF cells. In the case of
unpurified LF (i.e., in a complex with LPS), the TLR4-
dependent signaling pathway can be expected. In the
case of purified LF, the TLR4-dependent pathway can be
excluded. This statement is based on results of the
experiment in which a medium containing 1 picogram
of LPS per milliliter was used (pure LF medium). The
concentration was selected because the same residual
amount of LPS was detected by the LAL test in the case
of the purified form of LF. The results showed that this
amount had no impact on the MDMF activation.
mRNA production of IL-8 and TNFα by HEK0 and HEK4a
cells after unpurified LF treatment
Activation of the TLR4-dependent pathway was further
excluded in experiments using permanent cell lines
Table 1 Porcine primers used in the study
Gene Sequence 5′–3′ Reference
CXCL10/
IP10
F: CCC ACA TGT TGA GAT CAT TGC [55]
R: CAT CCT TAT CAG TAG TGC CG
HPRT F: GAG CTA CTG TAA TGA CCA GTC AAC G [56]
R: CCA GTC TCA ATT ATA TCT TCA ACA ATC AA
IL-8 F: TTC TGC AGC TCT TCG TGA GGC [57]
R: GGT GGA AAG GTG TGG AAT GC
NFκB F: ACG AGC AGA TGG TGA AGG AG [57]
R: TCA TGG ATG ATG GCC AAG T
TNFα F: CCC CCA GAA GGA AGA GTT TC [58]
R: CGG GCT TAT CTG AGG TTT GA
Table 2 Human primers used in the study
Gene Sequence 5′–3′ Reference
GAPDH F: TCC TAG ATT ATT CTC TGA TTT GGT CGT ATT G this study
R: GAA TTT GCC ATG GGT GGA ATC ATA TTG
IL-8 F: TCC AAA CCT TTC CAC CCC AAA TTT ATC this study
R: AGC TCT CTT CCA TCA GAA AGC TTT ACA ATA A
TNFα F: CAA TGG CGT GGA GCT GAG AGA TA this study
R: CCT TGA AGA GGA CCT GGG ATG AGA T
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HEK0 and HEK4a that express either no TLR molecules
or TLR4a-MD2-CD14 complex. As expected, stimulation
of HEK0 with LPS or with two concentrations of unpuri-
fied LF (LF-LPS complex) did not increase expression of
mRNA for TNFα and IL-8 (Fig. 2a, c). In the case of
HEK4a, this response was induced (Fig. 2b, d).
In contrast to results shown in Fig. 2b and d, expres-
sion of mRNA for pro-inflammatory cytokines was not
increased when purified LF was used (Fig. 3a, b). The
production of IL-8 and TNFα was increased only in the
case of unpurified LF and LPS, and it was partially
decreased by Polymyxin B (PMB).
Western blot
Western blot analysis confirmed that expression of
mRNA for pro-inflammatory cytokines in response to
LPS alone or unpurified LF (LF-LPS) was conducted via
TLR4 and NFκB pathway activation (Fig. 4). Moreover,
Western blot analysis also confirmed that MDMF, when
stimulated with purified LF, were activated via TLR4-
independent pathway. It is clear from the fact that NIK
associated with activation of alternative NFκB pathway
was present (Fig. 5).
Discussion
The aim of this study was to extend our knowledge
about immunomodulatory properties of LF and particu-
larly about the pathway used by LF free of LPS to stimu-
late macrophages to the production of proinflammatory
cytokines.
As expected, MDMF responded to the stimulation
with unpurified LF containing LPS by the production of
proinflammatory cytokines. To a lesser extent, these
cells were stimulated also by purified LPS-free LF. It
suggested that this stimulation is LPS independent so
does not use the TLR4 associated pathway. This was
confirmed when HEK4a cells were treated with purified
LPS-free LF. These cells expressing only TLR4 did not
increase the production of IL-8 and TNFa transcripts
when compared to control. TLR4-dependent activation
was observed only in the case when these cells were
stimulated with LF-LPS complex in a dose-dependent
Fig. 1 Expression of mRNA for IP10 (a), NFκBi (b), IL-8 (c) and TNFα (c) by porcine monocyte-derived macrophages after stimulation with: 1 μg/ml
of lipopolysaccharide (LPS); unpurified lactoferrin (LF unpur) and purified lactoferrin (LF pur) containing 4.10 EU/ml and 0.05 EU/ml, respectively.
Cells treated with medium containing 1 pg/ml of LPS (i.e. amount comparable with residual LPS-contamination of LF pur) or cultivated in LPS-free
medium were used. Data are shown as mean ± SD, n = 6. Different letters show statistical significance when compared with control (p < 0.05)
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Fig. 2 Expression of mRNA for IL8 (a and b) and TNFα (c and d) by HEK cell line expressing no TLR (a and c) or the same cell line expressing
TLR4a-MD2-CD14 (b and d) after stimulation with two concentrations of lactoferrin (LF) or 1 μg/ml of lipopolysaccharide (LPS). Data are shown as
mean ± SD of 5 repetitions. Different letters show statistical significance when compared with control (p < 0.05)
Fig. 3 Expression of mRNA for IL8 (a) and TNFα (b) by HEK cell line expressing TLR4a-MD2-CD14 after stimulation with 1 μg/ml of lipopolysaccharide
(LPS); unpurified lactoferrin (LF unpur) and purified lactoferrin (LF pur) containing 4.10 EU/ml and 0.05 EU/ml, respectively. Cells stimulated with
unpurified LF in combination with polymyxine B are marked as LF-PMB. Cells cultivated in LPS-free medium were used. Data are shown as mean ± SD
of 5 repetitions. Different letters show statistical significance when compared with control (p < 0.05)
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manner. This confirmed that LPS-free LF does not acti-
vate cells via TLR4 and suggested that it uses an alterna-
tive pathway. To confirm that, Western blot analyses
were used. Purified LPS-free LF uses an alternative path-
way which activates NIK (NF-κB-inducing kinase). NIK
forms a complex with phosphorylated IKK1 and IKK2,
subsequently leading to the phosphorylation of IκB and
translocation of NF-κB to the nucleus [32]. NIK is essen-
tial for alternative NFκB pathway, being required for the
processing of p100 to p52 [22]. Concerning LPS, it is
known that NIK induces phosphorylation of IKK1, that
in turn phosphorylates histone H3 [33]. It may be
relevant also for LF-LPS (unpurified LF) treatment.
Zarnegar and coworkers showed the relevance of NIK in
canonical NFκB pathway, when NIK is present at high
levels. They demonstrated elevation of canonical NFκB
pathway activity on TRAF3−/− mice. In this case NIK
was stabilized and present at high levels due to the defi-
ciency of TRAF3 [23]. TRAF3 is an essential negative
regulator of alternative NFκB pathway, but in the study
it was shown that TRAF3 suppresses canonical NFκB
activation and gene expression both in vitro and in vivo.
Deregulation of canonical pathway in TRAF3-deficient
cells causes NIK accumulation, i.e. TRAF3 inhibition
results in coordinated activation of both canonical and
alternative pathways [23]. NIK probably lies at a cross
road of the canonical and non-canonical pathways of
NFκB and it maintains the positive and negative regula-
tory balance between these two pathways. Maintaining
this balance is crucial for the proper physiological
responses [32, 34].
LF has no specific receptor on the surface of mono-
cytes/macrophages. It can bind to different low- or high-
affinity receptors. The similar route leading to NFкB
activation is conducted via RAGE (receptor for advanced
glycation endproducts) which is a multiligand receptor
expressed on macrophages, neurons, endothelial cells
and a variety of tumor cells [35, 36] and TREM-1 (triger-
ring receptor expressed on myeloid cells 1) a member of
the immunoglobulin superfamily which was found on
monocytes and neutrophils [37]. Signals which are con-
ducted via RAGE activate two major pathways. First one
comprises CDC42/Rac and the second one encompasses
MAPKs that finally lead to NFκB activation [38]. TREM-
1 is a positive regulator of inflammation [37]. One of the
main mechanisms mediating the expression of TREM-1
is activation of NFκB [39]. TREM-1 modulates the activ-
ity and availability of key proteins of the TLR4 signaling
cascade [40]. TREM-1 influences TLR4 signaling cascade
positively by driving TLR4 into the lipid rafts [41]. In
other words, signal conducted via TLR4, RAGE and
TREM-1 use connected patways and lead to NFκB
activation.
LF has the potential to modify the course of an infec-
tion [42]. Being immunomodulator, LF is used as adjunct
therapeutic which can alter the immune status of the
infected host. Bovine LF is widely used as therapeutic
agent or food additive in many animal or human models.
In the mouse model, it improves host survival modestly
concurrent with the decreased serum cytokines [43] or it
protects gut integrity in mouse models of LPS endotox-
aemia [44]. Its immunomodulatory properties were also
confirmed in the influence of low endotoxine bovine
milk LF (<0.2 EU/mg) on expression of presentation
molecules on bone marrow derived macrophages
Fig. 4 Presence of phosphorylated form of IκB in HEK cell line
expressing no TLR (left, HEK0) or the same cell line expressing
TLR4a-MD2-CD14 (right, HEK4a) after stimulation with (from left o
right) 1 μg/ml of lipopolysaccharide (LPS); 100 μg/ml of unpurified
(LF + LPS) or purified lactoferrin (LF pur) containing 4.10 EU/ml or 0.05
EU/ml, respectively. Cells cultivated in LPS-free medium were used as a
control. β-actin served as loading control
Fig. 5 Presence of phosphorylated form of NIK in porcine
monocyte-derived macrophages after stimulation with (from right to
left) 1 μg/ml of lipopolysaccharide (LPS); 100 μg/ml of purified
(LF) of unpurified lactoferrin (LF-LPS) containing 0.05 EU/ml or 4.10
EU/ml, respectively. Cells cultivated in LPS-free medium were used
as a control. β-actin served as loading control
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(BMMs) study. LF modulated the activity of macro-
phages and their ability to present an antigen and to
stimulate T-cells through increased surface expression of
antigen presentation and co-stimulatory molecules such
as CD80 and CD86. BMMs cultured with bovine LF
increased the number of MHC II+ cells [45].
In humans, LF is known to be able to prevent the on-
set of sepsis in infants [46–48]. LF has a high homology
among species [49] thus, heterologous molecules of LF
are used as a therapeutic agents. Although, the better
protective or immunomodulatory effect of homologous
recombinant LF could be expected, it was not proven,
concretely in the mouse model of methicillin-resistant
Staphylococcus aureus challenge. Recombinant mouse
LF (rmLF) and recombinant human LF (rhLF) had a
high degree of overlap to modulate inflammatory re-
sponses. Both recombinant molecules caused a decrease
in inflammatory cytokine production in monocytes and
an increase of cytokine production in granulocytes dur-
ing the infection. But the two heterologous recombinant
molecules showed some differences in their activities
concerning cellular population that were used in the
studies-mouse granulocytes demonstrated a different
cytokine pattern upon the infection than human granu-
locytes. LFs were produced under endotoxin free serum
conditions, and further affinity purified to remove traces
of endotoxin [42]. The data show that endotoxin-free LF
has not only immunomodulatory effects but also the
therapeutic effects which have different essence than just
LPS binding.
A similar study in which low endotoxin human milk
LF (<10EU/mg) was used supports a therapeutic signifi-
cance of LF in vivo. LF treatment reduced TNF-α and
IL-6 in serum of LPS-challenged mice during LPS-
induced endotoxaemia, when it was delivered to naive
mice 1 h prior to administration of LPS. The same mol-
ecule showed a prophylactic effect of treatment with LF
18 h prior to LPS-induced endotoxaemia when the pro-
duction of TNF-α but not IL-6 was affected [50].
Conclusion
Our results suggest that LF’s ability is not only to bind
LPS, but LF itself may be a stimulant of pro-
inflammatory pathways. LF’s ability to bind LPS from an
environment is known very well [16, 51]. This binding is
its natural property which is used for example against
bacterial infections. Due to this fact, LF often occurs in
an unpurified form in a complex with LPS [18]. This
kind of “contamination” resulting from one of the nat-
ural properties of LF could lead to some overvalued re-
sults. It should be considered when studying the
production of cytokines or chemokines after LF treat-
ment. Similar situations were found concerning other
therapeutic proteins. When testing ovalbumin, it was
found that a purified form of this protein did not acti-
vate endothelial cells in vitro. If an unpurified commer-
cial ovalbumin containing LPS was used, endothelial
cells were activated in early stages of inflammation [52].
False pro-inflammatory effects of commercial alpha-
lactalbumin were previously described in RAW 264.7
macrophages due to endotoxin contamination [53]. And,
finally, other authors mentioned contamination of com-
mercial LF [18, 54]. This fact should be borne in mind
when we perform experiments in which we study pro-
inflammatory parameters.
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